Is the onset of adverse effects of immunotherapy always bad news for the patients…?-certainly not!
作者信息
Hofman Paul
机构信息
Université Côte d'Azur, FHU OncoAge, CHU Nice, Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France.
Université Côte d'Azur, FHU OncoAge CNRS, INSERM, IRCAN, Team 4, Nice, France.
出版信息
Ann Transl Med. 2019 Mar;7(Suppl 1):S5. doi: 10.21037/atm.2019.01.14.
Abstract
摘要
相似文献
1
Is the onset of adverse effects of immunotherapy always bad news for the patients…?-certainly not!免疫疗法不良反应的出现对患者来说就总是坏消息吗……？当然不是！
Ann Transl Med. 2019 Mar;7(Suppl 1):S5. doi: 10.21037/atm.2019.01.14.
2
Challenges in delivering bad news in a multi-ethnic intensive care unit: An ethnographic study.多民族重症监护病房中传递坏消息的挑战：一项民族志研究。
Patient Educ Couns. 2019 Dec;102(12):2199-2207. doi: 10.1016/j.pec.2019.06.017. Epub 2019 Jun 28.
3
Emotional Intelligence and Delivering Bad News: The Jury is Still Out.情绪智力与传递坏消息：尚无定论。
J Surg Educ. 2019 May-Jun;76(3):779-784. doi: 10.1016/j.jsurg.2018.09.017. Epub 2018 Nov 3.
4
Nurses' perspectives on breaking bad news to patients and their families: a qualitative content analysis.护士对向患者及其家属告知坏消息的看法：一项质性内容分析
J Med Ethics Hist Med. 2014 Nov 12;7:18. eCollection 2014.
5
Breaking bad news in cancer patients.向癌症患者传达坏消息。
Indian J Palliat Care. 2015 Jan-Apr;21(1):35-8. doi: 10.4103/0973-1075.150172.
6
Breaking bad news: issues relating to nursing practice.告知坏消息：与护理实践相关的问题。
Nurs Stand. 2014 Jul 15;28(45):51-8. doi: 10.7748/ns.28.45.51.e8935.
7
Breaking Bad News: An Evidence-Based Review of Communication Models for Oncology Nurses.告知坏消息：肿瘤护理人员沟通模式的循证综述
Clin J Oncol Nurs. 2017 Oct 1;21(5):573-580. doi: 10.1188/17.CJON.573-580.
8
Development of a Web-Based Formative Self-Assessment Tool for Physicians to Practice Breaking Bad News (BRADNET).为医生开发一种基于网络的形成性自我评估工具，用于练习传达坏消息（BRADNET）。
JMIR Med Educ. 2018 Jul 19;4(2):e17. doi: 10.2196/mededu.9551.
9
Breaking Bad News to Patients with Intracranial Tumors: The Patients' Perspective.向颅内肿瘤患者告知坏消息：患者视角
World Neurosurg. 2018 Oct;118:e254-e262. doi: 10.1016/j.wneu.2018.06.168. Epub 2018 Jun 30.
10
Service users' experience of receiving bad news about their mental health.服务使用者在收到有关其心理健康的坏消息时的体验。
J Ment Health. 2010 Feb;19(1):34-42. doi: 10.3109/09638230903469137.
引用本文的文献
1
The Weighted Toxicity Score: Confirmation of a Simple Metric to Communicate Toxicity in Randomized Trials of Systemic Cancer Therapy.加权毒性评分：用于在系统癌症治疗随机试验中沟通毒性的简单指标的验证。
Oncologist. 2024 Jan 5;29(1):67-74. doi: 10.1093/oncolo/oyad192.
2
Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation.免疫相关不良事件的生物学基础以及与辐射免疫原性效应的潜在关联。
Front Pharmacol. 2021 Nov 1;12:746853. doi: 10.3389/fphar.2021.746853. eCollection 2021.
3
Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China.免疫相关不良事件及其与非小细胞肺癌中PD-1/PD-L1抑制剂疗效的关联：一项来自中国的真实世界研究。
Front Oncol. 2021 Mar 5;11:607531. doi: 10.3389/fonc.2021.607531. eCollection 2021.
4
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.纳武利尤单抗治疗转移性非小细胞肺癌免疫相关不良事件的相关结局：一项全球队列的汇总探索性分析。
Cancer Immunol Immunother. 2020 Jul;69(7):1177-1187. doi: 10.1007/s00262-020-02536-5. Epub 2020 Mar 5.
本文引用的文献
1
The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy.免疫治疗中肿瘤免疫与自身免疫的平衡作用
Cancer Immunol Res. 2018 Dec;6(12):1445-1452. doi: 10.1158/2326-6066.CIR-18-0487.
2
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.免疫相关不良事件对纳武利尤单抗治疗的晚期非小细胞肺癌患者生存的影响：多机构分析的长期结果。
J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485. doi: 10.1007/s00432-018-2805-3. Epub 2018 Dec 1.
3
Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?肿瘤突变负荷评估作为肺癌患者免疫治疗的预测生物标志物：是否已准备好进入黄金时代？
Transl Lung Cancer Res. 2018 Dec;7(6):631-638. doi: 10.21037/tlcr.2018.08.04.
4
Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.免疫检查点抑制剂相关性肺炎对 NSCLC 患者接受免疫检查点治疗生存的影响。
J Thorac Oncol. 2019 Mar;14(3):494-502. doi: 10.1016/j.jtho.2018.11.016. Epub 2018 Nov 30.
5
Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer.年龄对非小细胞肺癌患者免疫治疗结局的影响。
J Thorac Oncol. 2019 Mar;14(3):547-552. doi: 10.1016/j.jtho.2018.11.011. Epub 2018 Nov 23.
6
Predictors of immunotherapy-induced immune-related adverse events.免疫治疗诱导的免疫相关不良事件的预测因素。
Curr Oncol. 2018 Oct;25(5):e403-e410. doi: 10.3747/co.25.4047. Epub 2018 Oct 31.
7
Management of immunotherapy toxicities in older adults.老年人免疫疗法毒性的管理。
Semin Oncol. 2018 Aug;45(4):226-231. doi: 10.1053/j.seminoncol.2018.09.001. Epub 2018 Nov 13.
8
Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.外周血 TCR 谱分析可能有助于对黑色素瘤免疫治疗的患者进行分层。
Cancer Immunol Res. 2019 Jan;7(1):77-85. doi: 10.1158/2326-6066.CIR-18-0136. Epub 2018 Nov 13.
9
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy.循环细胞因子可预测接受抗 PD-1 免疫治疗的黑色素瘤患者的免疫相关毒性。
Clin Cancer Res. 2019 Mar 1;25(5):1557-1563. doi: 10.1158/1078-0432.CCR-18-2795. Epub 2018 Nov 8.
10
Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism.免疫疗法与超进展：不良结局，机制不明。
Clin Cancer Res. 2019 Feb 1;25(3):904-906. doi: 10.1158/1078-0432.CCR-18-3144. Epub 2018 Nov 5.
Zotero 插件